Skip to main content
. 2018 Apr 25;2:PO.17.00245. doi: 10.1200/PO.17.00245

Fig 4.

Fig 4.

Kaplan-Meier survival analysis for patients with hormone receptor–positive metastatic breast cancer by TP53 genotype in validation cohorts. (A) Recurrence-free survival in The Cancer Genome Atlas by TP53 mutation status. (B) Overall survival in an independent cohort of 98 patients with hormone receptor–positive metastatic breast cancer by TP53 mutation status. MUT, mutant; WT, wild type.